Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy
Background. One of the major challenges affecting sarcoma treatment outcome, particularly that of metastatic disease, is resistance to chemotherapy. Cancer-initiating cells are considered a major contributor to this resistance. Methods. An immortalised nontransformed human stromal (mesenchymal) stem...
Saved in:
Main Authors: | Ninna Aggerholm-Pedersen (Author), Christina Demuth (Author), Akmal Safwat (Author), Peter Meldgaard (Author), Moustapha Kassem (Author), Boe Sandahl Sorensen (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2016-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combination Treatment with Liposomal Doxorubicin and Inductive Moderate Hyperthermia for Sarcoma Saos-2 Cells
by: Valerii E. Orel, et al.
Published: (2024) -
Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
by: Keskin D, et al.
Published: (2016) -
Population Pharmacokinetics of Dasatinib in Healthy Subjects
by: Walaa B. Hassouneh, et al.
Published: (2024) -
Dasatinib self-assembled nanoparticles decorated with hyaluronic acid for targeted treatment of tumors to overcome multidrug resistance
by: Yawen Zhang, et al.
Published: (2021) -
Dasatinib in chronic myeloid leukemia: a review
by: Dolly G Aguilera, et al.
Published: (2009)